Anterior Pelvic Prolapse Reconstruction With TiLOOP® PRO A Polypropylene Mesh

pfm medical gmbh54 enrolled

Overview

The purpose of this study is to determine the influence of anterior pelvic prolapse reconstruction with a titanized polypropylene mesh on patients quality of life.

This multicentre, non-randomized, observational clinical investigation will be performed to obtain usability and postmarket information on the TiLOOP® pelvic floor reconstruction meshes and in particular to obtain the improvement of patients' quality of life. It is expected that the patient's quality of life is meliorated after implantation of a TiLOOP® PRO A mesh. To verify this, it will be shown that by means of a validated questionnaire the subjective quality of life after 12 months is significantly better than before implantation.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Cystocele Uterine Prolapse

Interventions

TiLOOP® PRO Plus ADEVICE

The standard operation method for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans-vaginally using the TiLOOP® Application Set to place the mesh arms.

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Existence of a cystocele. Women with a symptomatic genital descensus: at least stage II (ICS-classification according POP-Q system). This applies to primary as well as recurrent intervention. 2. Patient is mentally able to understand the nature, aims, or possible consequences of the clinical investigation. 3. Patient information has been handed out and written consent is at hand. 4. Patient has attained full age (18 years or older). Exclusion Criteria: 1. Unfinished family planning, pregnancy or breast-feeding mother. 2. Known intolerance to the mesh-implants under investigation. 3. Lack of written patients' informed consent. 4. Lack of patient compliance regarding data collection, treatment or follow-up investigations in the scope of the protocol. 5. Patients with acute (within the last 12 months) carcinoma in the pelvic area. 6. Patients with history of radiotherapy in the pelvic area. 7. Patients with implanted anterior pelvic floor mesh. 8. Patient is institutionalized by court or official order (MPG §20.3). 9. Participation in another interventional clinical investigation.

Locations (5)

Klinik Tettnang GmbH

Tettnang, Baden-Wurttemberg, Germany

Klinikum Augsburg

Augsburg, Bavaria, Germany

Klinikum Dresden-Friedrichstadt

Dresden, Saxony, Germany

Klinikum Oberlausitzer Bergland gemeinnützige GmbH

Zittau, Saxony, Germany

Outcomes

Primary Outcomes

Patient's Quality of Life

By means of a validated questionnaire it will be shown whether the subjective quality of life after 12 months is significantly better than before implantation.

Time frame: 12 months

Secondary Outcomes

Patient's Quality of Life

The evaluation of changes in quality of life assessed by the P-QoL 6 months after implantation of the TiLOOP® PRO A surgical mesh compared to before implantation.

Time frame: 6 months

Adverse Events (AE)

Assessment and analysis of all \[serious\] adverse events (\[S\]AEs) during the first 12 months after implantation along with a contextual placement of safety data based on current literature.

Time frame: 6 weeks, 6 and 12 months

Feasibility Check of Mesh implantation

To evaluate mesh implantation, information about the duration of the procedure (minutes from cut to stitches) and the operability of the application set (easy, suitable, difficult, no set used) will be collected during the surgery. Taking together, this information will encapsulate the feasibility of the mesh implantation descriptively.

Time frame: 1 day

Number of complications and concomitant procedures

Counting the number of intraoperative complications (e. g. lesion of the bladder, the urethra or the intestines) and concomitant procedures (e. g. hysterectomy, colporrhaphy, vaginal sacrospinal fixation) procedure-related adverse events as assessed by CTCAE v4.0 and common concomitant procedures will be evaluated.

Time frame: 1 day

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.